CoMFA and CoMSIA analyses on 4-oxo-1,4-dihydroquinoline and 4-oxo-1,4-dihydro-1,5-,-1,6-and-1,8-naphthyridine derivatives as selective CB2 receptor agonists

被引:19
作者
Cichero, Elena [1 ]
Cesarini, Sara [1 ]
Mosti, Luisa [1 ]
Fossa, Paola [1 ]
机构
[1] Univ Genoa, Dipartimento Sci Farmaceut, I-16132 Genoa, Italy
关键词
Cannabinoid receptor; CB2; agonist; CoMFA; CoMSIA; 3D-QSAR; CANNABINOID RECEPTORS; NEURODEGENERATIVE DISEASES; ANALGESIC ACTIVITY; BONE MASS; PAIN; TRANSMISSION; THERAPY; LIGANDS; POTENT; TARGET;
D O I
10.1007/s00894-009-0580-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Novel classes of CB2 agonists based on 4-oxo1,4- dihydroquinoline and 4-oxo-1,4-dihydro-1,5-, -1,6- and -1,8-naphthyridine scaffolds have shown high binding affinity toward CB2 receptor and good selectivity over CB1. A computational study of comparative molecular fields analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) was performed, in order to identify the key structural features impacting their binding affinity. The final CoMSIA model resulted to be the more predictive, showing r(ncv)(2) = 0.84, r(cv)(2) = 0.619, SEE=0.369, and r(pred)(2) = 0.75. The study provides useful suggestions for the synthesis of new selective analogues with improved affinity.
引用
收藏
页码:677 / 691
页数:15
相关论文
共 28 条
[1]  
Ashton JC, 2007, CURR OPIN INVEST DR, V8, P373
[2]   Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide [J].
Calignano, A ;
La Rana, G ;
Piomelli, D .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 419 (2-3) :191-198
[3]   The endocannabinoid system in targeting inflammatory neurodegenerative diseases [J].
Centonze, Diego ;
Finazzi-Agro, Alessandro ;
Bernardi, Giorgio ;
Maccarrone, Mauro .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2007, 28 (04) :180-187
[4]  
Cramer R D 3rd, 1989, Prog Clin Biol Res, V291, P161
[5]   Levels, metabolism, and pharmacological activity of anandamide in CB1 cannabinoid receptor knockout mice:: Evidence for non-CB1, non-CB2 receptor-mediated actions of anandamide in mouse brain [J].
Di Marzo, V ;
Breivogel, CS ;
Tao, Q ;
Bridgen, DT ;
Razdan, RK ;
Zimmer, AM ;
Zimmer, A ;
Martin, BR .
JOURNAL OF NEUROCHEMISTRY, 2000, 75 (06) :2434-2444
[6]   Cannabinoid CB2 receptor:: a new target for controlling neural cell survival? [J].
Fernandez-Ruiz, Javier ;
Romero, Julian ;
Velasco, Guillermo ;
Tolon, Rosa M. ;
Ramos, Jose A. ;
Guzman, Manuel .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2007, 28 (01) :39-45
[7]   Discovery of 2-[(2,4-Dichlorophenyl)amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]-4-(trifluoromethyl)-5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain [J].
Giblin, Gerard M. P. ;
O'Shaughnessy, Celestine T. ;
Naylor, Alan ;
Mitchell, William L. ;
Eatherton, Andrew J. ;
Slingsby, Brian P. ;
Rawlings, D. Anthony ;
Goldsmith, Paul ;
Brown, Andrew J. ;
Haslam, Carl P. ;
Clayton, Nick M. ;
Wilson, Alex W. ;
Chessell, Iain P. ;
Wittington, Andrew R. ;
Green, Richard .
JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (11) :2597-2600
[8]   Cannabinoids and Neuropathic Pain [J].
Goya, P. ;
Jagerovic, N. ;
Hernandez-Folgado, L. ;
Martin, M. I. .
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2003, 3 (07) :765-772
[9]   Cannabinoid CB2 receptors:: a therapeutic target for the treatment of inflammatory and neuropathic pain [J].
Guindon, J. ;
Hohmann, A. G. .
BRITISH JOURNAL OF PHARMACOLOGY, 2008, 153 (02) :319-334
[10]   Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus [J].
Hájos, N ;
Ledent, C ;
Freund, TF .
NEUROSCIENCE, 2001, 106 (01) :1-4